Biotech and Pharma

Gilead looks attractive again. Its innovative edge and new crop of medications are performing well across multiple specialties.

The surge in pharmaceutical stocks that followed the administration’s deal with Pfizer on Tuesday was still going strong on Wednesday.

Pharma stocks are on a tear. Technical indicators speak to further strength.

Government shutdown starts, Pfizer’s drug pricing deal could become industry template, risks from Trump’s tariffs, and more news to start your day.

The president announced a federal government website that allows Pfizer to sell medicines at low prices to cash-paying consumers.

Chip maker Wolfspeed says it has emerged from Chapter 11 bankruptcy.

Pfizer said last week it would pay $47.50 per share for Metsera, and an extra $22.50 per share if its drugs hit certain milestones.

Now it’s up to the White House to decide whether the pharmaceutical industry’s efforts to appease the administration over the past few months have gone far enough.

Emma Walmsley has overseen eight turbulent years at he U.K. drugmaker. The firm announced Monday that she will be succeeded by GSK insider and drug industry stalwart Luke Miels.

U.S. prescriptions for Novo's Ozempic and Wegovy drugs are stagnating, Morgan Stanley analysts said.

The biotechnology company reported that a drug meant to treat the skin condition hidradenitis suppurativa, or HS, didn’t have a statistically significant effect.

Genmab will acquire Merus in an all-cash transaction worth around $8 billion.

Federal government shutdown deadline looms, September jobs report could be delayed, Tesla reports EV deliveries, and more news to start your day.

The blockbuster medications could open a new frontier for the pharma giants.

Trump’s threat of a 100% tariff on imported branded or patented drugs sounds dramatic, yet, pharma stocks were mostly in the green as the past few months have already seen a flurry of companies announcing plans to invest in the U.S.

Eli Lilly rises after President Donald Trump announces a 100% tariff on drug products from companies not building manufacturing plants in the U.S.

Our annual Healthcare Roundtable sizes up the risks and opportunities as public policy shifts. 16 stocks to buy now.

Guardant’s screen could see annual sales of $50 billion. The company hopes to use the technology to detect hundreds of other diseases.

Companies fall into one of several categories: mental-health-care services, which run clinics or treatment centers; companies that offer digital or virtual care; and pharmaceutical companies.

New tariffs on drugs, building materials, Supreme Court urged to let Fed governor Lisa Cook keep her job, Amazon settles FTC lawsuit, and more news to start your day.

Alibaba jumps after unveiling plans to boost investments in artificial intelligence, while Lithium Americas soars on news that the Trump administration is seeking an equity stake in the company.

Thornburg International Equity also sees opportunities in European utilities.

“Independent, sound science clearly shows that taking acetaminophen does not cause autism,” a Kenvue spokesperson told Barron’s.

Technical indicators show three biotech stocks poised for further gains.

Nvidia strikes another deal, Miran believes Fed rate is way too high, Disney restores Jimmy Kimmel’s show, and more news to start your day.